Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Return on Capital Employed: 2017-2025

Historic Return on Capital Employed for Aclaris Therapeutics (ACRS) over the last 8 years, with Sep 2025 value amounting to -0.98%.

  • Aclaris Therapeutics' Return on Capital Employed fell 68.00% to -0.98% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.98%, marking a year-over-year decrease of 68.00%. This contributed to the annual value of -0.80% for FY2024, which is 30.00% down from last year.
  • Aclaris Therapeutics' Return on Capital Employed amounted to -0.98% in Q3 2025, which was down 11.27% from -0.88% recorded in Q2 2025.
  • Over the past 5 years, Aclaris Therapeutics' Return on Capital Employed peaked at -0.30% during Q3 2024, and registered a low of -0.98% during Q3 2025.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.55% (2023), whereas its average is -0.62%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first spiked by 66bps in 2021, then plummeted by 68bps in 2025.
  • Over the past 5 years, Aclaris Therapeutics' Return on Capital Employed (Quarterly) stood at -0.38% in 2021, then rose by 1bps to -0.38% in 2022, then fell by 17bps to -0.55% in 2023, then declined by 29bps to -0.84% in 2024, then slumped by 68bps to -0.98% in 2025.
  • Its Return on Capital Employed stands at -0.98% for Q3 2025, versus -0.88% for Q2 2025 and -0.75% for Q1 2025.